#USA #New York #Class Action #Levi Korsinsky #ADMA Biologics

Action on ADMA Biologics, Inc. (NASDAQ: ADMA) Class Action

Investors in ADMA Biologics, Inc. are being urged to join a class action lawsuit against the company due to serious allegations surrounding its revenue reporting and internal controls. The prominent law firm
Levi & Korsinsky, LLP is currently taking action for those who invested in ADMA between August 9, 2024, and March 25, 2026. The firm has highlighted that the company's public statements about revenue growth are being fundamentally challenged.

Background of the Case

In 2025, ADMA reported revenues of $362.5 million for its key product, ASCENIV. This figure suggested a promising growth rate of approximately 20% year-over-year, enticing many investors. However, a March 2026 report from Culper Research alleged that true revenue growth was much lower, estimating an actual decline of about 3%. This discrepancy is purportedly linked to an alleged channel stuffing scheme executed by ADMA.

What is Channel Stuffing?

Channel stuffing refers to the practice where a company sends more products to distributors than they can sell in order to inflate revenue figures. This can mislead investors about the true demand and health of the business. Allegations against ADMA suggest that the company may have engaged in such practices, leading to misrepresented financial statements and, consequently, investor losses.

The Allegations

The lawsuit asserts that ADMA misled investors on several fronts:

• - Revenue Recognition: ADMA stated that its revenue practices were compliant with accounting standards, implying that revenue was recognized only when control of products was transferred. This was called into question by the independent research alleging that actual sales figures fell significantly short.
• - Related Party Transactions: Allegations arose that ADMA failed to disclose sales involving related entities, which could indicate unethical financial practices. One of these entities, Genesis BioPharma Services, was allegedly tied to ADMA’s Vice Chairman, Jerrold Grossman, raising additional concerns about transparency.

The Implications for Investors

Given the allegations and the stark contrast between reported and reality revenues, the lawsuit aims to secure settlements for affected investors. Key points for investors to consider include:

• - Eligibility: Investors who purchased ADMA securities within the defined class period can join the suit, whether or not they still hold shares.
• - No Fees: Those interested in participating won’t face any upfront costs as class actions typically operate on a contingency basis, meaning fees are only collected if a recovery is achieved.
• - Lead Plaintiff Deadline: To have a more active role in the lawsuit, interested parties should note that the lead plaintiff deadline is August 10, 2026.

Next Steps for Investors

Investors affected by the situation are encouraged to gather their transaction details, including purchase dates and quantities. They should then reach out to Levi & Korsinsky for a free evaluation of their case. Moreover, anyone who sold their shares during the class period may still have a claim for their losses.

Contact Information

To begin the process, reach out to:

• - Joseph E. Levi, Esq. at [email protected] or call (212) 363-7500.
• - Free consultations are available to evaluate potential claims without any obligation.

Conclusion

The unfolding situation at ADMA Biologics, marked by allegations of financial misconduct, poses a crucial moment for investors seeking to reclaim their losses. By participating in the class action lawsuit, aggrieved shareholders may find the opportunity to recover from past grievances and hold the company accountable for its alleged misleading practices. Potential plaintiffs should act swiftly and keep an eye on the important deadlines associated with the lawsuit.